Theramex, a global speciality pharmaceutical company dedicated to women’s health, has signed an agreement with Enzene Biosciences Ltd., Pune, India, to register and commercialise denosumab for use in Europe, the UK, Switzerland, and Australia. Denosumab is a human monoclonal antibody and a biosimilar of the reference medicine Prolia®, an antiresorptive treatment for osteoporosis. As part of the agreement, Enzene will be the sole supplier of the finished product to Theramex.
The Pune (India) based biotechnology company will exclusively supply the product to Theramex for the duration of the agreement made to register and commercialise denosumab, a biosimilar of Prolia®, for use in Europe, the UK, Switzerland and Australia.
Denosumab is an antiresorptive treatment for osteoporosis administered bi-annually by a single subcutaneous injection. The human monoclonal antibody (IgG2) targets and binds to RANKL, preventing activation of RANK on the surface of osteoclast precursors and osteoclasts, and therefore osteoclast formation, function and survival.
“The addition of this biosimilar to our existing portfolio continues our strategic determination to improve access and affordability of important treatments to patients,” said Robert Stewart, Chief Executive Officer at Theramex.
Enzene’s Whole-Time Director, Himanshu Gadgil, added, “Enzene is dedicated to the development of affordable treatment options for patients. As such, I am delighted that Enzene and Theramex will be working together to provide women in Europe, the UK, Switzerland, and Australia with access to denosumab, a biosimilar treatment for osteoporosis.”
Theramex offers healthcare solutions to support women’s health through innovative and effective solutions ranging from contraception, fertility, menopause and osteoporosis.
About Enzene Biosciences Limited
Based in Pune, India, the innovation-driven biotech company is a subsidiary of Alkem Laboratories Ltd. The company produces biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals, with the aim of disrupting the cost barrier. It also offers CDMO and CMO services for biologics.